Aeterna Zentaris Reports First Quarter 2021 Financial
expected beyond 2023 CHARLESTON, S.C., May 05, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today reported its financial and operating results for the first quarter ended March 31, 2021. The Company also provided an update on its preclinical and clinical development programs. “Over the cour...
United Kingdom Klaus Paulini Novo Nordisk Biopharm Limited Aeterna Zentaris University Of Queensland Queensland University
Source: globenewswire.com